HIND Overview

Monthly Distributions Announcement: Harvest Portfolios Group Inc. has announced monthly distributions for various Harvest ETFs for November 2025, with payments scheduled for December 5, 2025, to unitholders of record on November 28, 2025.

Distribution Details: The distributions vary by ETF, with amounts ranging from $0.0250 to $0.4300 per unit, depending on the specific ETF and its currency denomination.

Estimated Distribution for Canadian T-Bill ETF: An estimated distribution of $0.0935 per unit for the Harvest Canadian T-Bill ETF will also be paid on December 5, 2025, with the final amount to be confirmed on November 27, 2025.

Company Background: Harvest Portfolios Group Inc., founded in 2009, manages over $9.6 billion in assets and focuses on long-term wealth preservation through high-quality business investments, utilizing various covered call strategies across its ETFs.

Corporate Milestones: Vyome Holdings successfully completed a streamlined Nasdaq listing and reported encouraging interim Phase 2 results for its drug VT-1953, aimed at treating malignant fungating wounds, while maintaining a disciplined cash burn rate that extends its runway through 2026.

Leadership and Strategy: The company appointed a new CTO and SVP of Clinical Development with extensive Big Pharma experience and launched an AI strategy through the acquisition of MIT startup Oculo, enhancing its capabilities in drug development.

Clinical Progress: VT-1953 demonstrated significant reductions in malodor and pain in patients, with plans for FDA discussions on pivotal study design and orphan drug designation in 2026, targeting a $1 billion market opportunity with no existing FDA-approved treatments.

Financial Overview: As of September 30, 2025, Vyome reported total cash of $5.7 million, a clean capital structure with no preferred stock, and a net loss primarily due to one-time merger-related expenses, reflecting a strong position for future growth.

Partnership Announcement: Vyome Holdings, Inc. has signed a Memorandum of Understanding with Embryyo Technologies to collaborate in the AI-enabled medical device market, combining their expertise to innovate smart medical devices.

Vision and Goals: Vyome aims to leverage its resources and experience in healthcare along with Embryyo's technology capabilities to enhance disease management and treatment standards globally.

Innovation Forum: The partnership will also host a global forum focused on AI-enabled medical device innovation for companies operating between the US and India, although the MoU is non-binding.

Company Backgrounds: Vyome focuses on transforming patient care for immuno-inflammatory conditions, while Embryyo specializes in medical device development and has a strong pipeline of early-stage technologies.

Partnership Announcement: Vyome Holdings and Embryyo Technologies have signed a Memorandum of Understanding (MoU) to collaborate in the AI-enabled medical device market, aiming to innovate and commercialize smart medical devices for improved disease management.

Vision and Goals: Vyome's Chairman, Krishna Gupta, emphasizes the importance of partnering with talented teams to address significant healthcare challenges, while Embryyo's CEO, Nishant Kumar, highlights their shared vision and ongoing development of transformative medical devices.

Innovation Forum: The partnership will include hosting a global innovation forum focused on AI-enabled medical devices, targeting companies along the US-India corridor, although the MoU remains non-binding and subject to conditions.

Company Backgrounds: Vyome is based in Cambridge, MA, focusing on immuno-inflammatory conditions, while Embryyo specializes in medical device innovation and has developed a strong pipeline of early-stage medical technology intellectual property.